As Drug Value Frameworks Gain Traction, Patients Seek More Input
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
You may also be interested in...
Cost considerations will be limited to those borne by patients under value framework that is expected to be used initially to support patient-clinician decisions on appropriate treatment.
The Institute for Clinical and Economic Review has invited feedback on its methodology for calculating a drug's recommended price range. Industry response has been critical, but pharma can no longer afford to merely oppose value frameworks. It needs to create strategies for a world in which such frameworks are a permanent and influential part of the pricing and reimbursement landscape.
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.